|Bid||2.1500 x 800|
|Ask||2.4400 x 800|
|Day's Range||2.3500 - 2.4700|
|52 Week Range||2.0700 - 6.5800|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||0.67|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. R2 Dermatology was founded in late 2014 by Pansend Life Sciences (a subsidiary of HC2 Holdings, Inc.) and Blossom Innovations. Since inception, R2 has generated substantial safety and efficacy studies in several multi-center clinical studies both in North America and Asia. In addition, R2 has received two US FDA 510(k) clearances for its clinical stage devices.
R2 Dermatology Products to be Commercialized and Distributed by Huadong Medicine Company Limited NEW YORK, June 13, 2019 -- HC2 Holdings, Inc. (“HC2”) (NYSE: HCHC), a.
Carlisle's (CSL) solid foothold in non-residential construction market and strength in aerospace and defense markets are likely to prove conducive to its performance.
HC2 Holdings, Inc. (NYSE:HCHC) shareholders should be happy to see the share price up 28% in the last month. But...
The New York-based company said it had a loss of 4 cents per share. The diversified holding company posted revenue of $491.4 million in the period. The company's shares closed at $2.48. A year ago, they ...
NEW YORK, May 07, 2019 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that its operating subsidiary DBM Global Inc. (OTC:DBMG), a family of.
PHOENIX, May 07, 2019 -- DBM Global Inc. (OTC: DBMG), a family of companies providing fully integrated steel construction services, and an operating subsidiary of HC2 Holdings,.
- First Quarter 2019 Consolidated Net Revenue Grew 8.3% Year-Over-Year to $491.4 Million - - Reaffirms 2019 Guidance for Construction Segment - NEW YORK, May 07, 2019 -- HC2.
NEW YORK, NY / ACCESSWIRE / May 7, 2019 / HC2 Holdings, Inc. (NYSE: HCHC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 5:00 PM Eastern Time. ...
HC2 Holdings (HCHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, April 23, 2019 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it will release its financial results for the first quarter 2019.
Announcement: Moody's announces completion of a periodic review of ratings of HC2 Holdings, Inc. New York, March 18, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of HC2 Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
HC2 Holdings, Inc. (NYSE:HCHC), which is in the construction business, and is based in United States, saw significant share price movement during recent months on the NYSE, rising to highsRead More...
HC2 Holdings (HCHC) delivered earnings and revenue surprises of -193.75% and 7.72%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The New York-based company said it had a loss of 36 cents per share. Losses, adjusted for non-recurring gains, were 47 cents per share. The diversified holding company posted revenue of $524.9 million ...
- Fourth Quarter 2018 Consolidated Total Net Revenue Grew 14.5% Year-Over-Year to $524.9 million -- Full Year 2018 Consolidated Total Net Revenue Grew 21.0% Over 2017 to $2.0.
Strength in the construction and energy segments is expected to aid HC2 Holdings' (HCHC) Q4 results. However, higher costs are an overhang on the stock.
NEW YORK, Feb. 28, 2019 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it will release its financial results for the fourth quarter and.
Danaher (DHR) intends to use proceeds from common stock offering and the mandatory convertible preferred stock offering to fund the BioPharma business buyout.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in HC2 Holdings,Read More...